Tumour sidedness and intrinsic subtypes in patients with stage II/III colon cancer: analysis of NSABP C-07 (NRG Oncology)

Background: We tested the association of colon tumour sidedness with prognosis and with molecular subtypes recently shown to be predictive of oxaliplatin benefit in stage III colon cancer. Methods: NSABP/NRG C-07 trial ( N =1603) was used to determine association of tumour sidedness with molecular s...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 2018-03, Vol.118 (5), p.629-633
Main Authors: Kim, S Rim, Song, Nan, Yothers, Greg, Gavin, Patrick G, Allegra, Carmen J, Paik, Soonmyung, Pogue-Geile, Katherine L
Format: Article
Language:English
Subjects:
692/699/67/1504/1885
692/699/67/1504/1885/1393
Biomedical and Life Sciences
Biomedicine
Cancer Research
Clinical Study
Colon cancer
Colorectal cancer
Drug Resistance
Epidemiology
Medical prognosis
Molecular Medicine
Oncology
Oxaliplatin
Survival
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: We tested the association of colon tumour sidedness with prognosis and with molecular subtypes recently shown to be predictive of oxaliplatin benefit in stage III colon cancer. Methods: NSABP/NRG C-07 trial ( N =1603) was used to determine association of tumour sidedness with molecular subtypes and recurrence-free survival (RFS) and overall survival (OS). Results: Sidedness was associated with molecular subtypes except stem-like/CMS4 subtype. Patients with stage III, left-sided tumours showed superior OS but not RFS. Sidedness was not associated with prediction of oxaliplatin benefit when combined with 5-Fu+LV. However, greater benefit from oxaliplatin was observed in a small subset of stage III patients with left-sided, enterocyte-subtype tumours (interaction HR=0.17, P =0.01). Conclusions: Sidedness was associated with molecular subtypes and was predictive of OS in stage III colon cancer but was not predictive of RFS or oxaliplatin benefit in C-07. Molecular subtypes may provide more predictive value for oxaliplatin benefit than tumour sidedness.
ISSN:0007-0920
1532-1827
DOI:10.1038/bjc.2017.448